Optic pathway glioma

Optic pathway glioma (OPG), also known as optic nerve glioma or visual pathway glioma, is a low-grade brain tumor that arises along the optic pathway, which includes the optic nerves, optic chiasm, optic tracts, and occasionally extends to the hypothalamus or other adjacent brain structures. These tumors are most commonly pilocytic astrocytomas (WHO grade I) and predominantly occur in children, typically before the age of 10. Approximately 50–70% of optic pathway gliomas occur in individuals with neurofibromatosis type 1 (NF1), a genetic condition caused by mutations in the NF1 gene on chromosome 17. The primary body systems affected include the visual system and the central nervous system. Key clinical features include progressive vision loss, proptosis (bulging of the eye), strabismus (misalignment of the eyes), nystagmus, optic disc pallor or swelling, and visual field deficits. When the tumor involves the hypothalamus, patients may experience precocious puberty, growth hormone deficiency, obesity, or other endocrine abnormalities. Some children may also develop hydrocephalus due to obstruction of cerebrospinal fluid flow, leading to increased intracranial pressure with symptoms such as headache, nausea, and vomiting. Management of optic pathway gliomas depends on tumor location, rate of progression, and the patient's age and visual function. Many NF1-associated OPGs remain stable or even regress spontaneously and may only require observation with regular ophthalmologic and neuroimaging surveillance. When treatment is necessary due to progressive vision loss or tumor growth, first-line therapy typically involves chemotherapy, most commonly a combination of carboplatin and vincristine. Targeted therapies such as MEK inhibitors (e.g., selumetinib) have shown promising results, particularly in NF1-associated tumors. Radiation therapy is generally avoided in young children due to the risk of long-term neurocognitive effects and secondary malignancies, but may be considered in older patients with refractory disease. Surgical resection is rarely feasible due to the tumor's location along critical visual structures, though it may be performed in select cases of large, exophytic tumors causing significant mass effect.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Optic pathway glioma